Poly(Beta-Amino Ester) Nanoparticles Enable Nonviral Delivery of CRISPR-Cas9 Plasmids for Gene Knockout and Gene Deletion

Yuan Rui,1 Mahita Varanasi,1 Shanelle Mendes,1 Hannah M. Yamagata,1 David R. Wilson,1 and Jordan J. Green1,2,3

1Department of Biomedical Engineering, Institute for NanoBioTechnology, Translational Tissue Engineering Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; 2Departments of Ophthalmology, Oncology, Neurosurgery, Materials Science & Engineering, and Chemical & Biomolecular Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA; 3Bloomberg–Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA

The CRISPR-Cas9 system is a powerful gene-editing tool with wide-ranging applications, but the safe and efficient intracellular delivery of CRISPR components remains a challenge. In this study, we utilized biodegradable poly(beta-amino ester) nanoparticles to codeliver plasmid DNA encoding Cas9 and short guide RNA (sgRNA), respectively, to enable gene knockout following a CRISPR-mediated cleavage at one genomic site (1-cut edit), as well as gene deletion following DNA cleavage at two sites flanking a region of interest (2-cut edits). We designed a reporter system that allows for easy evaluation of both types of edits: gene knockout can be assessed by a decrease in near-infrared fluorescent protein (iRFP) fluorescence, whereas deletion of an expression stop cassette turns on a red-enhanced nanolatern fluorescence/luminescence dual reporter. Nanoparticles enabled up to 70% gene knockout level. We demonstrate promising biodegradable nanoparticle formulations for gene editing. Our findings also provide new insights into the screening and transfection requirements for different types of gene edits, which are applicable for designing nonviral delivery systems for the CRISPR-Cas9 platform.

INTRODUCTION

The CRISPR-Cas9 gene-editing system consists of a short guide RNA (sgRNA) conferring target sequence specificity, which complexes with the Cas9 endonuclease to enable site-specific DNA cleavage.1-5 This could result in gene knockout following nonhomologous end joining (NHEJ) or in the presence of a repair template, gene knockin through homology-directed repair (HDR). The targeting of sgRNAs to two sites flanking a genomic region of interest can result in the complete removal of the gene segment following NHEJ, which could be important in the silencing of genetic elements with no open-reading frames, such as microRNAs or long noncoding RNAs.4,5 CRISPR-mediated gene editing is contingent upon nuclear colocalization of both the Cas9 protein and sgRNA, and efficient intracellular delivery of CRISPR components remains a challenge.

Viral vectors have been demonstrated to be effective for delivery but are more challenging to produce for both preclinical and clinical studies and restricted in cargo size. This is problematic, as the Cas9 gene is over 4 kb long, and delivery using adeno-associated viruses (AAVs; packaging capacity ~4.7 kb) sometimes requires that different CRISPR components be packaged in separate viral particles, introducing complexity and potentially reducing efficacy.6,7 Synthetic vectors are largely agnostic to cargo size, and several recent reports have demonstrated strategies for nonviral intracellular delivery of the CRISPR-Cas9 gene-editing platform. These include nanoparticle delivery of Cas9 and sgRNA as a ribonucleoprotein (RNP) complex8-12 or in the form of Cas9 mRNA and sgRNA13-14 Cas9 and sgRNA encoded in plasmid DNA are another delivery format for CRISPR gene editing. Plasmid DNA can be easily constructed using standard molecular cloning techniques to include different Cas9 structures,15,16 multiplex sgRNA,17 and transcriptional targeting elements for cell type-specific editing.18 Furthermore, large libraries of biomaterials previously used for plasmid DNA delivery can be screened for CRISPR gene editing in a high-throughput manner19 to yield optimal formulations for gene editing in different applications.

It is important to note that delivery of CRISPR gene-editing complexes in the form of plasmid DNA carries several potential safety concerns that must be taken into account when designing translationally relevant therapeutics. For example, there is a risk of plasmid DNA unintentionally integrating into the host genome, inducing insertional mutagenesis when highly active promoter elements are inserted into oncogenes or disrupt tumor-suppressor genes.20 Furthermore, plasmid DNA encoding Cas9 and sgRNA increases the persistence time of CRISPR RNPs inside the cell, which has been shown to increase off-target editing.21 In this respect, delivery of CRISPR...
gene-editing complexes in the form of mRNA or proteins has the benefit of low persistence time and reduced off-target editing. As effective nonviral delivery vehicles for miRNA or protein complexes are still somewhat lacking, however, CRISPR delivery in these formats can often suffer from low serum tolerance or poor in vivo efficacy.22 Although several studies have reported strategies for nonviral CRISPR plasmid delivery,18,23–26 most involve gene-knockout applications using sgRNA designed to enable cleavage at a single site, and none, to our knowledge, have investigated the transfection requirements for gene deletion after cleavage at multiple sites. In this study, we designed a novel reporter system for easy detection of gene knockout following CRISPR-mediated cleavage at one genomic site (1-cut edit), as well as gene deletion following DNA cleavage at two sites flanking a region of interest (2-cut edit). We used polymers (beta-amino esters) (PBAEs), a class of biodegradable cationic polymers that have been shown to be effective at plasmid DNA delivery27 for intracellular delivery of plasmid DNA encoding both the Cas9 endonuclease and sgRNA, respectively, and demonstrate that these polymeric nanoparticles enable efficient 1-cut, as well as 2-cut, edits. Moreover, we systematically varied transfection parameters to probe the relationship between the expression of CRISPR components and the subsequent efficacy of different types of CRISPR-mediated edits. Our results provide important insights on the threshold gene-expression levels required for 1- and 2-cut edits in easy-to-transfect, as well as hard-to-transfect, cell lines.

RESULTS

Polymeric Nanoparticles for Gene Delivery

Polymer 446, which has been shown previously to be effective at plasmid DNA delivery to a variety of cells,28,29 was used to transfect HEK293T cells (Figure 1A). The newly developed branched polymer 7,8-4-J11 enabled higher transfection efficacy in B16-F10 murine melanoma cells30 (Figure S1) and was used to transfect these cells. Both polymers formed nanoparticles 100–200 nm in diameter with positive zeta potentials (12–25 mV) (Figure 1B). Transfection efficacy, as assessed with a GFP reporter plasmid, showed that >80% cells were transfected in both cell lines (Figure 1C). However, when geometric mean fluorescence was used to quantify expression, 293T cells achieved expression that was nearly 1 order of magnitude higher than B16 cells.

Gene Knockout Following 1-Cut Edits

The efficiency of 1-cut edits was assessed in 293T cells constitutively expressing a destabilized form of GFP (GFPd2). GFPd2 is ubiquitinylated for rapid degradation and has a half-life (t1/2) of around 2 h (compared to a half-life of 26 h for wild-type GFP).31 This allows for rapid detection of gene knockout, which can be assessed by a decrease in GFP fluorescence following transfection with...
nanoparticles encapsulating two plasmids encoding the Cas9 endonuclease and a sgRNA targeting GFP, respectively. Nanoparticles codelivering both plasmids enabled coexpression, generating 70% gene knockout, as assessed by a decrease in GFP fluorescence, and 24% gene knockout, as assessed by Tracking of Indels by Decomposition (TIDE) analysis of genomic DNA; formulations delivering either component alone had negligible effects (Figure 2A). A kinetic study revealed that gene knockout reached maximal levels on day 3 and was maintained for over 3 weeks (Figure 2B). The Surveyor mutation detection assay was performed on cells treated with the combination nanoparticles or each component alone (Figure 2C) and confirmed that edits occurred only when both CRISPR components were delivered. Sanger sequencing revealed that most edits were single base-pair mutations and subsequent gene silencing.

Gain-of-Function Edits after 2-Cut Stop-Cassette Deletion

We designed a reporter system based on the Ai9 mouse in which an expression stop cassette consisting of two simian virus 40 (SV40) terminators in series was placed upstream of a red-enhanced nanoluciferin (ReNL) fluorescence-luminescence dual reporter (Figure 3A). This CRISPR-stop expression cassette was cloned into a piggyBac transposon plasmid to facilitate genomic integration at high efficiency after cotransfection using a piggyBac transposase plasmid. A near-infrared fluorescent protein (iRFP670) was also incorporated into the system as a selection marker for positively expressing cells during fluorescence-activated cell sorting (FACS). Thus, this system can be easily used to generate stably expressing reporter cell lines for rapid readout of knockout, as well as deletion mutations.

The sgRNA sequence sg1, which was designed to remove both SV40 sequences (cut sites indicated by blue arrows in Figure 3A) via a 630-bp deletion, resulted in turning on ReNL expression in nearly 50% of cells when cotransfected with the Cas9 plasmid. In contrast, nanoparticles targeting region highlighted in gray; protospacer adjacent motif (PAM) site highlighted in red.

Figure 2. 446 Nanoparticles Enable Sustained and Robust Gene Knockout in HEK293T Cells

(A) GFP knockout experiments in HEK-GFPd2 cells showed gene knockout only when plasmids coding for both components were delivered. Gene knockout was assessed by flow cytometry analysis of loss of GFP fluorescence and using TIDE analysis of Sanger sequencing data of genomic DNA of treated cells. n = 4; data presented as mean ± SEM. (B) Gene knockout was sustained over the 3-week experiment. n = 4. (C) Surveyor mutation detection assay confirms genomic DNA cleavage in the Cas9+/sgRNA+ treatment group. (D) Sanger sequencing of edited cells suggests that all edits were small indels. sgRNA targeting adjacent motif (PAM) site highlighted in red.
Expression Thresholds for 1-Cut and 2-Cut Edits

In order to assess the expression levels necessary to achieve 1-cut knockout edits and 2-cut gain-of-function edits, respectively, we varied the dosage of plasmid DNA delivered in nanoparticles. In 293T cells engineered to express the CRISPR-stop gene construct, a GFP reporter was used to gauge transfection levels. Results showed that lowering the total DNA dose from 600 to 300 ng did not change the percentage of cells positively expressing GFP, but the geometric mean of fluorescence decreased by nearly 50% (Figure 5A). This effect can be observed in flow cytometry histograms as the 300-ng treatment yielded a larger population of cells with low GFP fluorescence compared to the 600-ng treatment (Figure 5D, left panel). The lowering of the total DNA dose significantly decreased levels of 2-cut deletion edits (Figure 5B) but did not significantly change the levels of 1-cut knockout edits (Figure 5C).

We varied the total DNA dose delivered over a wider range in order to probe more thoroughly the effect of transfection efficacy on gene-editing levels (Figure 6A). The plotting of percent editing as a function of Cas9 mRNA expression levels revealed a logarithmic relationship for 1-cut edits \( (R^2 = 0.9550) \) and a linear relationship for 2-cut edits \( (R^2 = 0.9195) \). Transfection levels were further varied by manipulating cellular metabolic rates through incubation temperature variation (Figure 6B). Cells were transfected using the same nanoparticle formulation delivering the same DNA dose, after which, they were either incubated at standard 37°C or treated with a transient “cold shock” via incubation at 30°C. Transfection efficacy, as measured by Cas9 mRNA expression levels, increased significantly in cold-shocked cells; the same trend was observed for the level of 2-cut edits. Interestingly, cold shock treatment did not significantly change the level of 1-cut editing efficiency, which is consistent with the results from dose-titration experiments.

1-cut knockout of iRFP expression and 2-cut gain-of-function edits were also performed on B16-F10 murine melanoma cells, which achieved lower levels of transfection compared to 293T cells. This was seen both when transfection was assessed using the geometric mean fluorescence of GFP expression when using a GFP reporter gene for nanoparticle screening (Figure 1), as well as the level of Cas9 mRNA expression (Figure 4; Figure S5). The lower transfection level in B16 cells was reflected, most notably, in the results for 2-cut editing, where the ReNL fluorescence observed in B16 cells was 1 order of magnitude lower than 293T cells (Figures 6C and 6D). Interestingly, the effect of lower transfection efficacy was less pronounced for 1-cut iRFP knockout experiments. Although lower knockout levels were observed in B16 compared to 293T cells, the difference was much smaller (12% for B16 and 33% for 293T). Representative flow cytometry histograms showed that in 293T cells, 1-cut editing produced a new iRFP-negative peak, whereas no such peak was observed in B16 cells, which showed an overall population shift of iRFP expression (Figure 6E). Since each cell very likely contains several copies of iRFP integrated into the genome, the peak in 293T cells indicates that 1-cut editing produced a small
population of cells with complete iRFP knockout, whereas the edited population in B16 cells lost some but not all copies of iRFP, and the incomplete iRFP knockout in this population resulted in a general shift in fluorescence. Combined, this validates results seen earlier with dose titration, as well as temperature-modulation experiments, and confirms our hypothesis that 1-cut knockout edits require a lower expression threshold compared to 2-cut edits.

Standard transfection reagents were also used to assess 2-cut editing efficiency. For both cell lines, the commercially available cationic polymer transfection reagent jetPrime resulted in significantly lower editing levels than PBAE nanoparticles (Figure S7). The commercially available cationic lipid transfection reagent Lipofectamine 3000 enabled significantly higher editing than the earlier-generation linear PBAE polymer 446 in 293T cells but did not achieve significantly higher levels of editing than the newly developed next-generation branched PBAE polymer 7,8-4-J11 in harder-to-transfect B16 cells. Notably, Lipofectamine 3000 caused significantly higher levels of cytotoxicity than both PBAE nanoparticle formulations, further demonstrating the advantage of using a biodegradable gene-delivery system.

A Multiplex tRNA-Guide RNA (gRNA) Expression System
To facilitate a simpler method for multiplex CRISPR editing, we designed a tRNA-gRNA expression system, which utilizes the cell’s endogenous tRNA processing machinery to generate multiple sgRNAs (Figure 7A). With the use of a simple Golden Gate assembly strategy, we created a plasmid in which the targeting sequences and gRNA scaffolds of sg2 and sg3 are arrayed in tandem with pre-tRNA, with all components governed by a single U6 promoter. Mature gRNA is released after processing of the primary RNA transcript by tRNA-processing RNases. When transfected into cells alongside the Cas9 plasmid, this tRNA-gRNA plasmid enabled similar levels of 2-cut editing as the plasmid in which a U6 promoter governed each sgRNA (Figure 7B). This demonstrates that the multiplex tRNA-gRNA expression system effectively expressed both sgRNAs required for 2-cut editing.

DISCUSSION
In this work, we demonstrated that both linear and branched PBAE nanoparticles, codelivering two DNA plasmids encoding Cas9 and sgRNA, respectively, can achieve efficient gene editing in both 1-cut knockout, as well as 2-cut gene-deletion applications. We created a novel CRISPR-stop reporter system that can be used to assess both types of edits: an iRFP fluorescent reporter can be silenced by indels after 1-cut edits, whereas an expression stop cassette upstream of a ReNL reporter can be deleted using 2-cut gene editing. This expression cassette was cloned into a piggyBac transposon system and can be used to generate stably expressing cell lines.

Figure 4. Expression Kinetics of CRISPR Components after Codelivery of Cas9 and sg1 Plasmids in 293T Cells
(A–D) Cas9 mRNA (A; red curve) and protein expression (A, blue curve; B) were measured over time in HEK293T cells. (C) sgRNA and (D) ReNL mRNA expression kinetics. n = 2 for qRT-PCR experiments; n = 1 for western blots.

www.moleculartherapy.org
mRNA delivery of CRISPR components in the form of plasmid DNA.18,23 To date, only 3 studies have reported the use of polymeric nanoparticles, including a different PBAE formulation,38 to deliver CRISPR gene-editing components. Several recent studies have demonstrated the feasibility of using polymeric nanoparticles to achieve this type of deletion has not been previously reported. The use of nonviral delivery vectors for 2-cut gene deletion by delivering Cas9 mRNA and sgRNA14 or RNP complexes,12,37 but plasmid delivery of its downstream products. With the use of this strategy, we showed successful codelivery of CRISPR plasmids that enabled robust 1-cut gene knockout (Figure 2). More importantly, we demonstrated a versatile gene-deletion platform in which a single sgRNA targeting site flanking the region of interest and a combination of sgRNA targeting sites throughout the region of interest both resulted in successful removal of the entire gene segment (Figure 3). Successful deletion of up to 630 bp could be easily visualized through the gain-of-function expression of a ReNL fluorescence/luminescence dual reporter.

Evaluation of the expression kinetics of Cas9 and sgRNA revealed that Cas9 mRNA was maintained at high levels throughout the time period tested (4.5–48 h), whereas sgRNA expression reached peak levels at 48 h and plateaued thereafter (Figure 4). The plateau observed in the expression of sgRNA (but not Cas9) in the short term is likely due to a difference in the expression kinetics of the U6 promoter driving sgRNA expression compared to the cytomegalo- virus (CMV) promoter driving Cas9 expression. After a slower start, sgRNA rapidly accumulated inside the cell, eventually reaching a plateau, at which point, the expression of additional copies of sgRNA was likely balanced out by plasmid dilution through cellular division. This is a common pattern seen in transient gene expression induced by nanoparticle transfection,40 and we would expect expression levels of both Cas9 and sgRNA to drop at longer time points. Indeed, when we evaluated Cas9 protein accumulation at longer time points, we found that Cas9 protein levels declined steadily after 48 h and were virtually undetectable at 11 days post-transfection (Figure S6). Compared to delivery of CRISPR components in mRNA or protein form, where Cas9 protein expression decreased to below levels of detection after 3 days,24 the long Cas9 persistence time following plasmid DNA delivery raises concerns of off-target editing.

Figure 5. DNA Dosage Titration Reveals Different Threshold Expression Requirements for 1-Cut and 2-Cut Edits

(A) DNA dosage decrease from 600 ng to 300 ng did not change the overall percentage of GFP-positive cells but significantly decreased the geometric mean of expression. (B and C) Dosage decrease significantly decreased the efficacy of 2-cut gene deletion edits (B) but not 1-cut iRFP knockout edits (C). Statistical significance determined by Holm-Sidak corrected multiple t tests; **p < 0.01, ***p < 0.001. Data presented as mean ± SEM; n = 4. (D) Flow cytometry plots of cells treated with different DNA doses.

Threshold Expression Requirements for 1-Cut and 2-Cut Edits

Several recent studies have demonstrated the feasibility of using polymeric nanoparticles, including a different PBAE formulation,38 to deliver CRISPR gene-editing components in the form of plasmid DNA. All of these systems have exclusively investigated the use of 1-cut editing to achieve gene knockout, and none has presented a systematic study of the expression levels required for 1-cut and 2-cut edits. The removal of a gene segment requires sgRNA to target two sites flanking the region of interest and is significantly more difficult than 1-cut knockout edits. To date, only 3 studies have reported the use of nonviral delivery vectors for 2-cut gene deletion by delivering Cas9 mRNA and sgRNA or RNP complexes,12,25 but plasmid delivery with polymeric nanoparticles to achieve this type of deletion has not been previously reported. The use of DNA plasmids to encode Cas9 overcomes the manufacturing challenges of producing large scales of Cas9 mRNA or Cas9 protein, but the intracellular delivery and expression of exogenous DNA can be more challenging than the delivery of its downstream products.

We evaluated two types of PBAE nanoparticles to encapsulate Cas9 and sgRNA plasmids for intracellular delivery of gene-editing complexes. One of these was the well-published linear PBAE polymer 446 that has shown efficacy in multiple cell types, and one was a newly developed branched PBAE polymer 7,8-4-J11; both were found to be useful for developing efficacious biodegradable nanoparticles for gene editing. The cationic polymer and anionic DNA self-assembled into nanoparticles 100–200 nm in diameter with positive zeta potentials (12–25 mV) (Figure 1). Previous reports have shown that high levels of codelivery can be achieved by pre-mixing plasmids prior to nanoparticle assembly.39 With the use of this strategy, we showed successful codelivery of CRISPR plasmids that enabled robust 1-cut gene knockout (Figure 2).

(A) DNA dosage decrease from 600 ng to 300 ng did not change the overall percentage of GFP-positive cells but significantly decreased the geometric mean of expression. (B and C) Dosage decrease significantly decreased the efficacy of 2-cut gene deletion edits (B) but not 1-cut iRFP knockout edits (C). Statistical significance determined by Holm-Sidak corrected multiple t tests; **p < 0.01, ***p < 0.001. Data presented as mean ± SEM; n = 4. (D) Flow cytometry plots of cells treated with different DNA doses.

Development and Characterization of a New PBAE Nanoparticle System

with the use of two cell lines stably expressing this construct—easy-to-transfect HEK293T and hard-to-transfect B16-F10—we further investigated the transfection requirements for each type of gene editing.

Development and Characterization of a New PBAE Nanoparticle System

...
It is important to note that the risk of off-target editing following synthetic nanoparticle delivery of CRISPR plasmids is significantly lower than when viral vectors are used for gene editing. However, these risks can be further mitigated by using Cas9 variants41,42 that have been engineered to have enhanced proofreading and lower off-target editing rates compared to wild-type Cas9.

We further explored the transfection requirements for 1-cut and 2-cut edits by titrating the total DNA dose delivered. Interestingly, the decrease of total DNA dose from 600 ng to 300 ng significantly decreased the level of 2-cut editing but did not affect the level of 1-cut edits (Figure 5). The same trend was observed when transfection efficiency was varied by treating transfected cells with a minor cold shock (Figure 6). A brief cold shock slowed the rate of cellular division, which enhanced protein accumulation in expressing cells and decreased the rate of plasmid DNA dilution in the cell population. This increased transfection efficiency and the level of 2-cut edits, which is consistent with previous reports using cold shock treatment to enhance the editing efficiency of zinc-finger nuclease (ZFN)-mediated gene disruption 43 or CRISPR-mediated, homology-directed repair.44 In contrast, cold shock treatment did not significantly change the efficiency of 1-cut edits. Recent studies on the enzyme kinetics of sgRNA-Cas9 RNPs have reported that whereas Cas9-sgRNA binding ($k = 6.1 \text{ s}^{-1}$), target DNA binding ($t_{1/2} = 4–40 \text{ s}$), and DNA cleavage events ($k = 25–90 \text{ s}^{-1}$) happen very quickly,45 the release of DNA cleavage products is extremely slow ($t_{1/2} = 43–91 \text{ h}$),46 causing Cas9 to be virtually a single turnover enzyme. Taken together with these results, our data suggest that 2-cut edits have a much higher expression threshold than 1-cut edits, because twice the number of DNA cleavage events are required for successful edits to occur.

The expression thresholds of 1-cut and 2-cut edits have important implications on gene editing in different cell types. To demonstrate this, we compared the gene-editing efficiency in easier-to-transfect HEK293T and harder-to-transfect B16-F10 cells. HEK293T cells were derived from the parent HEK293 human embryonic kidney cell line and further modified with the SV40 large T antigen.47 The SV40 large T antigen causes plasmid DNA containing the SV40 origin of replication to unwind inside HEK293T cells, allowing for plasmid DNA replication and high levels of transfection.48 HEK293T cells are widely known to be an easy-to-transfect cell line and are commonly used for the production of recombinant proteins49 and viral vectors50 after transient plasmid DNA transfection using commercially available transfection reagents. B16-F10 cells, commonly used for tumor inhibition studies, are a well-established murine melanoma cell line.51 B16-F10 cells have been reported to be much more difficult to transfect with nonviral vectors,52 which is, in part, due to significantly lower nanoparticle uptake levels (Figure S8).

Although the top nanoparticle formulation for each cell line achieved >80% transfection, as assessed by percentage of total cells transfected, the level of expression, as assessed by the normalized geometric mean of expression of a GFP reporter, was 1 order of magnitude higher for 293T cells (Figure 1). This discrepancy was reflected in the level of 2-cut edits, as B16 cells showed very minimal levels of ReNL expression after stop-cassette deletion (Figure 6). In contrast, the difference...
in editing efficiency between the two cell lines was much smaller for 1-cut iRFP knockout (<3-fold difference compared to nearly 44-fold difference for 2-cut edits). These results further validate our hypothesis that the efficiency of 2-cut edits correlates more strongly with the level of DNA expression. Taken together, we have demonstrated that low levels of DNA transfection severely limit 2-cut editing efficiency.

One solution for improving 2-cut editing efficiency is to deliver CRISPR components in the RNP form, which we recently demonstrated enabled >40% 2-cut editing in B16 cells after nanoparticle delivery of CRISPR RNPs targeted to excise the transcription stop cassette.53 This demonstrates that bypassing limits in DNA transfection altogether may be a viable way to achieve efficient 2-cut editing in hard-to-transfect cell lines such as B16 cells.

Finally, we designed and implemented a tRNA-gRNA plasmid in which the expression of multiplex sgRNAs is governed under a single U6 promoter. The expression of two sgRNAs required for turning on ReNL fluorescence in these tRNA-gRNA tandem repeats enabled similar levels of editing compared to that of a plasmid in which each sgRNA is governed by its own U6 promoter (Figure 7). This expression system has the advantage of ease of synthesis, as upward of 6 sgRNAs can be arranged in tandem using a single Golden Gate assembly reaction.17 More importantly, the tRNA-gRNA system reduces the need for repeating U6 promoters, enabling the use of a much smaller plasmid construct, especially at high numbers of sgRNAs. Originally developed for use in rice plants,17 this system has also been adapted for use in yeast24 and zebrafish.55 To our knowledge, this is the first time it has been adapted for gene editing in mammalian cells.

In summary, we have demonstrated that PBAE nanoparticles codelivering plasmids encoding Cas9 and sgRNA can achieve 1-cut knockout, as well as 2-cut deletion edits. We designed a novel reporter system, whereby both modes of edits can be easily evaluated. 2-cut deletion events required much higher levels of transfection than 1-cut gene knockout edits, which we demonstrated by titrating the DNA dosage delivered, treating transfected cells with a transient cold shock, and comparing editing efficiencies in two cell lines with different transfection efficacy. The PBAE/DNA nanoparticles optimized here are promising for DNA-based nonviral gene editing. Further, the results presented herein have implications on the design and screening of next-generation nonviral delivery vehicles broadly for CRISPR-Cas9 gene editing.

MATERIALS AND METHODS

Materials
Small molecules used as monomers for polymer synthesis were obtained as follows: bisphenol A glycerolate (1 glycerol/phenol) diacrylate (B7; 411167), trimethylolpropane triacrylate (B8; 246808), 2-(3-aminopropylamino)ethanol (E6; 09293), and N,N-diethyldiethylenetriamine (J11; 518832)56 were purchased from Sigma-Aldrich; 1,4-butanediol diacrylate (B4; 32780) and 4-amino-1-butanol (S4; A12680) were purchased from Alfa Aesar. The following plasmids were purchased from Addgene: hCas9 (41815),3 gRNA_GFP-T2 (41820),3 pCAG-GFPd2 (14760), 31 PBCAG-EGFP (40973), 57 piRFP670-N1 (45457), 35 and tubulin-ReNL_pcDNA3 (89530). 58 PB-CMV-MCS-EF1a-RFP PiggyBac plasmid (PB512B-1) and PiggyBac transposase expression plasmid (PB200A-1) were purchased from System Biosciences. sgRNA gBlock sequences were purchased from Integrated DNA Technologies (IDT), and the expression stop cassette was synthesized by Synbio Technologies (Monmouth Junction, NJ, USA). Restriction enzymes and T4 DNA ligase for molecular cloning were purchased from New England BioLabs.

Polymer Synthesis
Polymer 446 was synthesized by reacting monomers B4 and S4 at a molar ratio of 1:1 at 90 °C with stirring overnight. The B4-S4 polymer was dissolved in anhydrous tetrahydrofuran (THF) at 167 mg/mL and added to monoclon E6 (0.5 M in THF) at a 3:2-volume ratio and reacted at room temperature for 1 h. The end-capped polymer was washed in diethyl ether twice to remove unreacted monomers and oligomers. Solvents were removed in a vacuum desiccant
chamber, and polymer was dissolved in DMSO at 100 mg/mL and then stored at −20°C with desiccant. Polymer 7,8-4-J11 was synthesized by reacting monomers B7, B8, and S4 at an overall vinyl:amine ratio of 2.2:1 and monomer concentration of 200 mg/mL in anhydrous DMSO at 90°C with stirring overnight; the acrylate monomer composition was 80% B7 and 20% B8 by mole fraction. Polymer end-capping and purification were done following the same procedure as polymer 446 but using monomer J11.

**Nanoparticle Characterization**

Nanoparticle hydrodynamic diameter was measured via dynamic light scattering (DLS) using a Malvern Zetasizer NanoZS (Malvern Instruments). Samples were prepared in 25 mM sodium acetate (NaAc) (pH 5.0) and then diluted 1:6 in 150 mM PBS to determine the hydrodynamic diameter in neutral, isotonic buffer. Zeta potential was measured by electrophoretic light scattering on the same instrument. Transmission electron microscopy (TEM) images were captured using a Philips CM120 (Philips Research) on 400 square mesh carbon-coated TEM grids. Samples were prepared at a polymer concentration of 1.8 mg/mL at 30 w/w in 25 mM NaAc, and 30 μL was allowed to coat TEM grids for 20 min. Grids were then rinsed with ultrapure water and allowed to dry fully before imaging.

**Cell Culture and Cell Line Preparation**

HEK293T and B16-F10 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Thermo Fisher Scientific), supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. Cells were induced to express fluorescent protein constructs constitutively using the PiggyBac transposon/transposase system. The GFPd2 gene was cloned into the PBS12B-1 plasmid using restriction enzyme cloning to create a PiggyBac transposon plasmid containing the GFPd2 gene. A sequence containing iRFP and transcription stop sequences was cloned into the PBCAG-EGFP plasmid backbone, and the ReNL gene was inserted into this plasmid using restriction enzyme cloning to create a PiggyBac transposon plasmid containing the iRFP-STOP-ReNL sequence (plasmid available on Addgene). Each transposon plasmid was cotransfected with the PiggyBac transposase plasmid into HEK293T and/or B16-F10 cells using nanoparticles, described below. Fluorescent protein signal from DNA not integrated into the cell genome was allowed to fade over 5 passages, after which, positive cells were isolated using FACS. Cells were further expanded for 3 more passages and sorted again to generate stably expressing cell lines.

**sgRNA Design and Preparation**

Single guide RNAs were designed using the [http://chopchop.cbu.ubc.ca](http://chopchop.cbu.ubc.ca) platform and ordered as gBlocks containing the U6 promoter, a unique 20-bp targeting sequence, and the duplex optimized sgRNA scaffold from IDT. The gBlocks were cloned into the pCAG-GFPd2 plasmid backbone using restriction enzyme cloning. sgRNA plasmids were transformed into DH5α competent *E. coli* (NEB) and grown out overnight at 37°C in 5 mL Luria-Bertani (LB) broth liquid cultures, and plasmid DNA was harvested using the QIAprep Miniprep Kit (QIAGEN). Plasmid DNA was characterized using the NanoDrop spectrophotometer (Thermo Fisher Scientific) and sequence confirmed via Sanger sequencing before use in transfections. All sgRNA target sequences are listed in Table S2, and plasmids are available on Addgene.

The gRNA-tRNA plasmid containing multiplex sgRNA constructs under a single U6 promoter was synthesized according to the protocol by Xie et al. Briefly, the pGTR construct containing a sgRNA scaffold sequence, fused to a tRNA fragment, was synthesized as a gBlock from IDT and cloned into a plasmid via restriction enzyme cloning. This pGTR plasmid was used as the template DNA for PCR reactions that produced amplicons used in a hierarchical Golden Assembly process to generate a DNA fragment containing the tRNA-gRNA tandem arrays. This fragment was then cloned into a backbone plasmid containing a U6 promoter via restriction enzyme cloning. The sequences for the pGTR sequence and PCR primers used are listed in Table S3.

**Transfection**

Cells were plated at 15,000 cells per well (HEK293T) or 10,000 cells per well (B16-F10) in 100 μL complete medium in CytoOne 96-well plates (USA Scientific) and allowed to adhere overnight. Polymers and DNA were dissolved separately in 25 mM NaAc at the desired concentrations and then mixed together via pipetting. Nanoparticles were allowed to self-assemble for 10 min, and then 20 μL of the nanoparticle solution was added per well for a final volume of 120 μL and 600 ng DNA per well, unless otherwise noted; for transfection experiments using the CRISPR-Cas9 system, the Cas9 and sgRNA plasmids were used at a 1:1 weight ratio. For example, in order to formulate nanoparticles that would deliver 600 ng DNA per well in 96-well plates at a polymer-to-DNA weight ratio of 60 (60 w/w), plasmid DNA was first dissolved in 25 mM NaAc at 0.06 mg/mL and polymer dissolved at 3.6 mg/mL. These two solutions were then mixed at a 1:1 volume ratio and allowed to self-assemble into nanoparticles. The Nitrogen to Phosphate (N/P) ratio is 34.5 for the 446 60-w/w formulation and 14.5 for the 7,8-4-J11 30-w/w formulation (Calculation S1). Nanoparticles were incubated with cells for 2 h at 37°C, at which point, the media and nanoparticles were removed and replaced with fresh complete media. Commercially available transfection reagents jetPrime (Polyplus) and Lipofectamine 3000 (Thermo Fisher Scientific) were used as instructed by the manufacturer. For cold shock treatment, cells were transfected using standard transfection procedures and allowed to recover at 37°C after media change for 6 h before being moved to 30°C. Cells were maintained at 30°C for 3 days, after which time, they were moved back to 37°C.

Transfection and gene-editing efficiencies were evaluated via flow cytometry using a BD Accuri C6 flow cytometer (BD Biosciences). For nanoparticle screening experiments using a GFP reporter gene, transfection was quantified via two methods: (1) the percentage of cells positively expressing GFP when gated against untreated cells was reported as % positive expression, and (2) the geometric mean fluorescence intensity in the FL1 channel (corresponding to GFP) for each treated well was normalized against that of untreated control.
wells, and the normalized geometric mean expression was reported. CRISPR knockout was quantified by normalizing the geometric mean fluorescence of treated wells to that of wells transfected with the Cas9 plasmid only. Gain of fluorescence was quantified as the percentage of cells positively expressing the fluorescent protein when gated against untreated control. Gene editing in gene-deletion experiments was also assessed by luminescence readings using the Promega Nano-Glo Luciferase assay system (Promega), measured with a Synergy2 plate reader (Biotek) with open optics and normalized to untreated control. Cell viability was assessed 24 h post-transfection using the MTS CellTiter 96 Aqueous One cell proliferation assay (Promega) (n = 4 ± SEM). Unless otherwise stated, flow cytometry to assess gene editing efficacy was performed on day 3 post-transfection.

**Surveyor Assay**

Genomic DNA from cells transfected with the combination Cas9-sgRNA plasmids and untransfected control was isolated using the GeneJET genomic DNA purification kit (Thermo Fisher Scientific). A 660-bp region flanking the predicted cut site was PCR amplified, and the PCR products were purified using the QIAquick PCR purification kit. 400 ng of PCR amplicons was hybridized, and the Surveyor assay was performed using the Surveyor mutation detection kit (IDT), following the manufacturer’s instructions. The uncut and cut DNA products were then run on a 2% agarose gel stained with ethidium bromide in Tris/borate/EDTA (TBE) buffer and imaged under UV light.

**TIDE Analysis to Assess 1-Cut Editing Efficiency**

Sanger sequencing was performed on purified PCR products from Surveyor assays. Sequencing data were uploaded to the online TIDE analysis tool (https://tide.deskgen.com) to assess 1-cut editing efficiency.

**Gel Electrophoresis Assay to Assess 2-Cut Editing Efficiency**

Genomic DNA from 293T-CRISPR-stop cells transfected with Cas9 and sgRNA plasmids or untransfected controls was isolated as described above. An 800-bp region flanking the predicted cut sites was PCR amplified, and PCR products were purified as described above. Standard gel electrophoresis was performed on PCR products using 2% agarose gel stained with ethidium bromide in TBE buffer at 80 V for 45 min and imaged under UV light to reveal unique banding patterns (Figure 3C). Band intensities were quantified using ImageJ image processing software, and % editing was calculated using the method reported by Schumann et al. Edits where >450 bp were deleted were quantified as Effective Edits, leading to gain-of-function ReNL expression, whereas all deletion edits were quantified as Total Edits for each sample.

**Sanger Sequencing to Detect Gene Editing**

PCR products for the Surveyor assay were cloned into plasmid vectors using the NEB PCR Cloning kit and transformed into DH5α-competent E. coli (NEB). 30 colonies were grown out in 5 mL liquid cultures overnight, and the plasmid DNA was isolated and characterized by Sanger sequencing.

**qRT-PCR**

Cells transfected with the combination Cas9-sgRNA plasmids in a 12-well plate were collected, and total RNA, including small RNAs (<100 nt), were extracted using the miRNeasy Mini Kit (QIAGEN). RNA was reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad), and qRT-PCR was run on a StepOnePlus Real-Time PCR system (Thermo Fisher Scientific) using SYBR Green PCR Master Mix (Thermo Fisher Scientific). The qPCR program is as follows: 95°C for 10 min; 95°C 15 s, 55°C 30 s, and 60°C 30 s for 40 cycles. Primers used for qRT-PCR are listed in Table S1. Results are shown as fold expression over β-actin.

**Western Blotting**

Transfected cells in 12-well plates were lysed in a solution of 1× radioimmunoprecipitation assay (RIPA) buffer and 1× Protease/Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). The lysate was cleared by centrifugation, protein concentration was determined using Pierce Micro BCA assay (Thermo Fisher Scientific), and samples were denatured in Laemmli sample buffer (Bio-Rad) in the presence of DTT. 50 μg proteins was loaded into 4%–15% Mini-PROTEAN TGX Precast Protein Gels (Bio-Rad). Proteins were then transferred to a polyvinylidene fluoride (PVDF) membrane using a Pierce Power Blotter (Thermo Fisher Scientific). Membranes were blocked in 5% nonfat milk for 1 h at room temperature (RT) and probed with primary antibodies against Cas9 (Cell Signaling Technologies; 14697; 1:500) or β-actin (Abcam; ab8226; 1:10,000) at 4°C overnight. Secondary antibodies were applied at RT for 1 h (mouse immunoglobulin G kappa binding protein conjugated to horseradish peroxidase [m-IgGc BP-HRP]; Santa-Cruz; Sc-516102; 1:1,000). The membrane was developed with Amersham ECL (enhanced chemiluminescence) Western Blotting Detection Reagent (GE Healthcare) and imaged using an ImageQuant LAS 4000 CCD (charge-coupled device) imager (GE Healthcare). Semiquantitative analysis of Cas9 protein expression was done by calculating band intensities using ImageJ image analysis software and normalizing the intensity of Cas9 bands to that of β-actin.

**Statistics**

Prism 8 (GraphPad, La Jolla, CA, USA) was used for all statistical analyses and curve plotting. The statistical test used and number of experimental replicates are detailed in the captions for each figure. Statistical significance was denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

**SUPPLEMENTAL INFORMATION**

Supplemental Information can be found online at https://doi.org/10.1016/j.omtn.2020.04.005,

**AUTHOR CONTRIBUTIONS**

Conceptualization, Y.R., D.R.W., and J.J.G.; Methodology, Y.R., D.R.W., and J.J.G.; Investigation, Y.R., M.V., S.M., H.M.Y., and
REFERENCES

1. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., and Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821.

2. Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., and Doudna, J. (2013). RNA-programmed genome editing in human cells. Elife 2, e00471.

3. Mali, P., Yang, L., Evert, K.M., Aach, J., Guell, M., DiCarlo, J.E., Norville, J.E., and Church, G.M. (2013). RNA-guided human genome engineering via Cas9. Science 339, 823–826.

4. Ho, T.-T., Zhou, N., Huang, J., Koirala, P., Xu, M., Fung, R., Wu, F., and Mo, Y.-Y. (2015). Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell nuclei. Nucleic Acids Res. 43, e17.

5. Dang, Y., Jia, G., Choi, J., Ma, H., Anaya, E., Ye, C., Shankar, P., and Wu, H. (2015). Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency. Genome Biol. 16, 280.

6. Yang, Y., Wang, L., Bell, P., McMenemy, D., He, Z., White, J., Yu, H., Xu, C., Morizono, H., Musunuru, K., et al. (2016). A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat. Biotechnol. 34, 334–338.

7. Yu, W., Mookherjee, S., Chaitankar, V., Hiriyanna, S., Kim, J.-W., Brooks, M., Ataieiannati, Y., Sun, X., Dong, L., Li, T., et al. (2017). Nl knockout by AAV-delivered CRISPR/Cas9 prevents retinal degeneration in mice. Nat. Commun. A. 14716.

8. Sun, W., Ji, W., Hall, J.M., Hu, Q., Wang, C., Beisel, C.L., and Gu, Z. (2015). Self-assembled DNA nanoclosers for the efficient delivery of CRISPR-Cas9 for genome editing. Angew. Chem. Int. Ed. Engl. 54, 12029–12033.

9. Zsiris, J.A., Thompson, D.B., Shu, Y., Guilinger, J.P., Bessen, J.L., Hu, J.H., Maeder, M.L., Wong, J.K., Chen, Z.Y., and Liu, D.R. (2015). Cationic lipid-mediated delivery of proteins enables efficient protein-based genome editing in vitro and in vivo. Nat. Biotechnol. 33, 73–80.

10. Wang, M., Zsiris, J.A., Meng, F., Rees, H., Sun, S., Deng, P., Han, Y., Gao, X., Poudi, D., Wu, Q., et al. (2016). Efficient delivery of genome-editing proteins using bioadreable lipid nanoparticles. Proc. Natl. Acad. Sci. USA 113, 2868–2873.

11. Lee, K., Conboy, M., Park, H.M., Jiang, F., Kim, H.J., Dewitt, M.A., Mackley, V.A., Chang, K., Rao, A., Skinner, C., et al. (2017). Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair. Nat. Biomed. Eng. 1, 889–901.

12. Mout, R., Ray, M., Yesiliag Tonga, G., Lee, Y.-W., Tay, T., Sasaki, K., and Rotello, V.M. (2017). Direct Cytosolic Delivery of CRISPR/Cas9-Ribonucleoprotein for Efficient Genome Editing. ACS Nano 11, 2452–2458.

13. Jiang, C., Mei, M., Li, B., Zhu, X., Xu, W., Tian, Y., Wang, Q., Guo, Y., Dong, Y., and Tan, X. (2017). A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and pck9 in vivo. Cell Res. 27, 440–443.

14. Miller, J.B., Zhang, S., Kos, P., Xiong, H., Zhou, K., Perelman, S.S., Zhu, H., and Siegwart, D.J. (2017). Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA. Angew. Chem. Int. Ed. Engl. 56, 1059–1063.

15. Shen, B., Zhang, W., Zhang, J., Zhou, J., Wang, J., Chen, L., Wang, L., Hodgkins, A., Iyer, V., Huang, X., and Skarnes, W.C. (2014). Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat. Methods 11, 399–402.

16. Konermann, S., Brigham, M.D., Trevino, A.E., Jung, J., Abudayyeh, O.O., Barcena, C., Huso, P.D., Habib, N., Gootenberg, J.S., Nishimasu, H., et al. (2015). Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature 517, 583–588.

17. Xie, K., Minkenberg, B., and Yang, Y. (2015). Boosting CRISPR/Cas9 multiplex editing capability with the endogenous tRNA-processing system. Proc. Natl. Acad. Sci. USA 112, 3570–3575.

18. Luo, Y.-L., Xu, C.-F., Li, H.-J., Cao, Z.-T., Liu, J., Wang, J.-L., Yu, X.-J., Yang, X.-Z., Gu, Z., and Wang, J. (2018). Macrophage-Specific in Vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles. ACS Nano 12, 994–1005.

19. Steyer, B., Carlson-Stevermer, J., Angenent-Mari, N., Khalil, A., Harkness, T., and Saha, K. (2016). High content analysis platform for optimization of lipid mediated CRISPR-Cas9 delivery strategies in human cells. Acta Biomater. 34, 143–158.

20. Yin, H., Kanasty, R.L., Elroukhyy, A.A., Vegas, A.J., Dorkin, J.R., and Anderson, D.G. (2014). Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541–555.

21. Liang, X., Potter, J., Kumar, S., Zou, Y., Quintanilla, R., Mante, J., Chen, W., Roark, N., Ranganathan, S., et al. (2015). Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J. Biotechnol. 208, 44–53.

22. Rui, Y., Wilson, D.R., and Green, J.J. (2019). Non-Viral Delivery To Enable Genome Editing. Trends Biotechnol. 37, 281–293.

23. Liang, C., Li, F., Wang, L., Zhang, Z.-K., Wang, C., He, B., Li, J., Chen, Z., Shaikh, A.B., Liu, L., et al. (2017). Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolypeptide for therapeutic genome editing of VEGFA in osteosarcoma. Biomaterials 147, 68–85.

24. Kim, S.M., Yang, Y., Oh, S.I., Hong, Y., Seo, M., and Jang, M. (2017). Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting. J. Control. Release 266, 8–16.

25. Timin, A.S., Mudislov, A.R., Lepik, K.V., Epifanovskaya, O.S., Shakirova, A.I., Mock, U., Riecken, K., Okilova, M.V., Sergeev, V.S., Afanaseyev, B.V., et al. (2018). Efficient gene editing via non-viral delivery of CRISPR/Cas9 system using polymeric and hybrid microcarriers. Nanomedicine (Lond.) 14, 97–108.

26. Rui, Y., Wilson, D.R., Sanders, K., and Green, J.J. (2019). Reducible Branched Ester-Amine Quatopolymer (bREAP) Codelivery Plasmid DNA and RNA Oligonucleotides Enable CRISPR-Cas9 Genome Editing. ACS Appl. Mater. Interfaces 11, 10472–10480.

27. Sunshine, J.C., Peng, D.Y., and Green, J.J. (2012). Uptake and transfection with polymeric nanoparticles are dependent on polymer end-group structure, but largely independent of nanoparticle physical and chemical properties. Mol. Pharm. 9, 3375–3383.

28. Sunshine, J.C., Akanda, M.I., Li, D., Kozielski, K.L., and Green, J.J. (2011). Effects of base polymer hydrophobicity and end-group modification on polymeric gene delivery. Biomacromolecules 12, 3592–3600.

29. Wilson, D.R., Mosenia, A., Suprenant, M.F., Upadhya, R., Routkevitch, D., Meyer, R.A., Quinones-Hinojosa, A., and Green, J.J. (2011). Continuous microfluidic assembly of biodegradable poly(beta-amino ester)/DNA nanoparticles for enhanced gene delivery. J. Biomed. Mater. Res. A 105, 1813–1825.

30. Wilson, D.R., Rui, Y., Siddiq, K., Routkevitch, D., and Green, J.J. (2019). Differentially Branched Ester Amine Quatopolymer with Amphiphilic and pH-Sensitive Properties for Efficient Plasmid DNA Delivery. Mol. Pharm. 16, 655–668.

31. Matsuda, T., and Cepko, C.L. (2007). Controlled expression of transgenes introduced by in vivo electroprocreation. Proc. Natl. Acad. Sci. USA 104, 1027–1032.

32. Madisen, L., Zwingman, T.A., Sunkin, S.M., Oh, S.W., Zariwala, H.A., Ha, G., Ng, L.L., Palmiter, R.D., Hawrylycz, M.J., Jones, A.R., et al. (2010). A robust and highthroughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 13, 133–140.
33. Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E.J., Hatanaka, F., Yamamoto, M., Arakawa, T., Li, Z., et al. (2016). In vivo genome editing via CRISPR/Cas9 mediating homology-independent targeted integration. Nature 540, 144–149.

34. Yusa, K., Zhou, L., Li, M.A., Bradley, A., and Craig, N.L. (2011). A hyperactive piggyBac transposase for mammalian applications. Proc. Natl. Acad. Sci. USA 108, 1531–1536.

35. Shcherbakova, D.M., and Verkhusha, V.V. (2013). Near-infrared fluorescent proteins for multicolor in vivo imaging. Nat. Methods 10, 751–754.

36. Kettlun, C., Galvan, D.L., George, A.L., Jr., Kaja, A., and Wilson, M.H. (2011). Manipulating piggyBac transposon chromosomal integration site selection in human cells. Mol. Ther. 19, 1636–1644.

37. Staahl, B.T., Benekareddy, M., Coulon-Bainier, C., Banfal, A.A., Floor, S.N., Sabo, J.K., Urnes, C., Munares, G.A., Ghosh, A., and Doudna, J.A. (2017). Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes. Nat. Biotechnol. 35, 431–434.

38. Zhu, D., Shen, H., Tan, S., Hu, Z., Wang, L., Yu, L., Tian, X., Ding, W., Ren, C., Gao, C., et al. (2018). Nanoparticles based on poly (β-amino ester) and HPV16 targeting CRISPR/shRNA as potential drugs for HPV16 related cervical malignancy. Mol. Ther. 26, 2443–2455.

39. Bhise, N.S., Shmueli, R.B., Gonzalez, J., and Green, J.J. (2012). A novel assay for quantifying the number of plasmids encapsulated by polymer nanoparticles. Small 8, 367–373.

40. Tzeng, S.Y., Guerrero-Cázares, H., Martínez, E.E., Sunshine, J.C., Quinones-Hinojosa, A., and Green, J.J. (2011). Non-viral gene delivery nanoparticles based on poly(β-amino esters) for treatment of glioblastoma. Biomaterials 32, 5402–5410.

41. Chen, J.S., Dadgas, Y.S., Kleinstiver, B.P., Welch, M.M., Sousa, A.A., Harrington, L.B., Sternberg, S.H., Joung, J.K., Yildiz, A., and Doudna, J.A. (2017). Enhanced proof-reading governs CRISPR-Cas9 targeting accuracy. Nature 550, 407–410.

42. Kleinstiver, B.P., Pattanayak, V., Prew, M.S., Tsai, S.Q., Nguyen, N.T., Zheng, Z., and Joung, J.K. (2016). High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529, 490–495.

43. Doyon, Y., Choi, V.M., Xia, D.F., Vo, T.D., Gregory, P.D., and Holmes, M.C. (2010). Transient cold shock enhances zinc-finger nuclease-mediated gene disruption. Nat. Methods 7, 459–460.

44. Guo, Q., Mintier, G., Ma-Edmonds, M., Storton, D., Wang, X., Xiao, X., Kienzle, B., Zhao, D., and Feder, J.N. (2018). 'Cold shock' increases the frequency of homology directed repair gene editing in induced pluripotent stem cells. Sci. Rep. 8, 2080.

45. Meckler, V., Minaklin, L., Semenova, E., Kuznelevod, K., and Severinov, K. (2016). Kinetics of the CRISPR-Cas9 effector complex assembly and the role of 3'-terminal segment of guide RNA. Nucleic Acids Res. 44, 2837–2845.

46. Raper, A.T., Stephenson, A.A., and Suo, Z. (2018). Functional Insights Revealed by the Kinetic Mechanism of CRISPR/Cas9. J. Am. Chem. Soc. 140, 2971–2984.
Supplemental Information

Poly(Beta-Amino Ester) Nanoparticles Enable Nonviral Delivery of CRISPR-Cas9 Plasmids for Gene Knockout and Gene Deletion

Yuan Rui, Mahita Varanasi, Shanelle Mendes, Hannah M. Yamagata, David R. Wilson, and Jordan J. Green
Supplemental Information

Supplemental Data:

Figure S1. GFP transfection screen results for B16-F10 cells.
Figure S2. TIDE quantification of indel frequencies.
Figure S3. Expression timeline for 2-cut edits.
Figure S4. Microscopy images of ReNL gain of expression.
Figure S5. Expression kinetics of CRISPR components in B16 cells.
Figure S6. Long-term Cas9 accumulation in 293T cells.
Figure S7. Comparison to commercial transfection reagents.
Figure S8. Nanoparticle uptake in B16 and 293T cells.

Table S1. PCR primer sequences
Table S2. Addgene plasmid numbers
Table S3. Primer and template sequences for tRNA-gRNA plasmid.

Calculation S1. N-P ratios of PBAE/DNA nanoparticles
Figure S1. GFP transfection screen results for B16-F10 cells. Fluorescence microscopy images (A) and flow cytometry results (B) show that branched PBAE polymer 7,8-4-J11 (30 w/w) transfects B16 cells more efficiently than canonical linear PBAE polymer 446 (60 w/w). Data presented as mean + SEM; N = 4. Scale bar = 200 μm.

Figure S2. TIDE quantification of indel frequencies. Sanger sequencing data of the genomic DNA of HEK-GFP cells treated with nanoparticles delivering CRISPR plasmids were quantified by TIDE analysis. N = 3, data presented as mean ± SEM.
Figure S3. ReNL expression time course after 2-cut edits in HEK cells. HEK cells were transfected on day 0 and gain of ReNL expression was monitored on selected days to determine the expression timeline for ReNL. N = 4, data presented as mean ± SEM.

Figure S4. Microscopy images of ReNL gain of expression. 2-cut CRISPR cleavage with sg1 or combination of sg2+sg3 turn on expression of ReNL by removal of two SV40 polyA sequences. Scale bar = 200 μm.
Figure S5. Expression kinetics of CRISPR components in B16 cells. mRNA expression levels of sgRNA (A) and ReNL (B). Cas9 mRNA (C, red curve) and protein (C, blue curve; D) expression levels over time. N = 2 (data shown as mean ± SEM) for qRT-PCR experiments; N=1 for western blots.

Figure S6. Long-term Cas9 accumulation in 293T cells. Western blotting was performed on indicated days after transfection of Cas9 and sgRNA plasmids in HEK-293T cells and Cas9 protein expression levels were quantified as fold expression over β-actin based on image analysis of band intensities (n=1).
Figure S7. Comparison to commercial transfection reagents. Gain of expression from 2-cut edits and viability of cells using commercial reagents and PBAEs in (A) 293T and (B) B16 cells as measured by ReNL luminescence. Data presented as mean + SEM; N=4. Statistical significance assessed by one-way ANOVA with Dunnett post-hoc tests as compared to the PBAE treated group (446 or J11, respectively); *p < 0.05, ****p < 0.0001.

Figure S8. Nanoparticle uptake analysis in B16 and 293T cells. Flow cytometry analysis of cellular uptake of nanoparticles encapsulating 20% Cy5-labeled DNA. Data shown as mean + SEM; N=4. Statistical significance assessed by one-way ANOVA with Sidak’s post-hoc tests; **p < 0.01, **** p < 0.0001.
| Target          | Sequence                                                                 | Notes                      |
|-----------------|---------------------------------------------------------------------------|----------------------------|
| GFP             | FWD: CTGGTCGAGCTGGACGGCGACG<br>REV: CACGAACTCCAGCAGGACCATG                 | Amplicon size: 630 bp      |
| 2X-SV40 Stop    | FWD: CGCAAATGGGCCGCTAGGGCTG<br>REV: GCCCTTGCTCACCATGAATT                  | Amplicon size: 755 bp      |
| Cassette        |                                                                          |                            |
| hCas9           | FWD: GGAGTTGACGCAAAGCAGAATCC<br>REV: AGATTTAAAAGTTGGGGGTGTCAGCC           | Amplicon size: 150 bp      |
| ReNL            | FWD: ATCCCCGTATGAAAGTTGCTGAGCG<br>REV: GTGATCATGTTCGCGTAACC               | Amplicon size: 147 bp      |
| sgRNA1          | FWD: ACATTATACGTTTCAGAGC<br>REV: GACTCGGTGCACTTTTCA                      | Amplicon size: 91 bp       |
| β-actin (human) | FWD: CATGTACGTTGCTATCCAGGC<br>REV: CTCCTTAATGTCAGCAGCAGT                 | Amplicon size: 250 bp      |
| β-actin (mouse) | FWD: CTGTCCCTGTATGCCCTGCTTC<br>REV: ATGTCACGCACGATTTC                    | Amplicon size: 218 bp      |

Table S1. PCR primer sequences.
| Plasmid Name            | Addgene ID | Description                                                                                                                                 |
|------------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| PB-iRFP-STOP-ReNL      | 113965     | Piggybac transposon plasmid CRISPR gene deletion activatable fluorescence. Constitutive iRFP670 under EF1A promoter, CMV promoter with two SV40 polyA followed by red-enhanced nanolantern (ReNL) |
| sg1                    | 113966     | Single short guide RNA targeting GTATAGCATACATTATACG                                                                                         |
| sg2                    | 133967     | Single short guide RNA targeting TACCACATTITGTAGAGGTT                                                                                       |
| sg3                    | 133968     | Single short guide RNA targeting CAATGTATCTTTATCATGTC                                                                                       |
| sg1+sg2+sg3            | 133969     | Triple short guide RNA targeting GTATAGCATACATTATACG, TACCACATTITGTAGAGGTT & CAATGTATCTTTATCATGTC                                             |
| sg2+sg3                | 133970     | Double short guide RNA targeting TACCACATTITGTAGAGGTT & CAATGTATCTTTATCATGTC                                                               |
| sgiRFP1                | 133972     | Single short guide RNA targeting GATCGAGTTTCGAGCCTGCGG in iRFP670 sequence                                                                   |
| sgiRFP2                | 133973     | Single short guide RNA targeting GCGCGTTCITTGGACGCGA in iRFP670 sequence                                                                     |
| sgiRFP3                | 133974     | Single short guide RNA targeting CGTGATTTTTACCGCTTC in iRFP670 sequence                                                                    |

Table S2. Plasmids deposited with Addgene
| DNA Sequence | Description and notes |
|--------------|-----------------------|
| ATTATTTGACCTAGTGGGTTTAGAGCTTAGAAATAGCAAGTTAAATAAGGCTAGTCCGGTTATCAACTTGAAAAAGTGGCACCAGAGTCGGTGCAAACAAAGCACCAGTGCTTGAGTTAGTGAAATAGGTCGGTGAAGATAGTATCCCTGCCACCGTACAGACCCGGGTTCGATTCCCGGGCTGGTGCA | pGTR sequence SpeI restriction enzyme site HindIII restriction enzyme site gRNA scaffold pre-tRNA |
| AGTTAGTTctegaAACAAGCACCGAGCTGGGGCTAGTCCAAGTTAAAATAAGGCTAGTCCGGTTATCAACTTGAA | tRNA-start_F primer XbaI restriction enzyme site |
| GAACCTCTACAAATGTGGTA | sg2 protospacer sequence; overlapping base pairs used in Golden Gate primers |
| TAGTCTCCACAAATGTGGTATGTTTAGAGCTAGAA | sg2_F primer |
| ATGGTCTCCATTGTAGAGTTCTGCACCAGCCGGGAA | sg2_R primer |
| GCAATGTAATCTTATCATGTCC | sg3 protospacer sequence; overlapping base pairs used in Golden Gate primers |
| TAGTCTCCCTTATCATGTCTGTTTAGAGCTAGAA | sg3_F primer |
| ATGGTCTCAAAAGATACATGGTGCACCAGCCGGGAA | sg3_R primer |
| CAATGTATAagcttaaaaaaaaaagCACCGAGCTCG | gRNA-end_R primer HindIII restriction enzyme site |

Table S3. DNA and primer sequences used to generate multiplex tRNA-gRNA plasmid. The pGTR sequence was cloned into a backbone plasmid via restriction enzyme cloning using SpeI and HindIII. The pGTR plasmid was then used as the PCR template for amplifying gRNA-tRNA sequences for Golden Gate assembly. To synthesize a multiplex plasmid containing both sg2 and sg3, PCR amplicons were generated using the following pairs of primers: tRNA-start_F + sg2_R (amplicon 1); sg2_F + sg3_R (amplicon 2); sg3_F + gRNA-end_R (amplicon 3). Amplicons 1-3 were then purified, ligated by Golden Gate assembly, and cloned into a backbone vector containing a single U6 promoter using restriction enzyme cloning with XbaI and HindIII.

Calculation S1. N-P ratios of PBAE/DNA nanoparticles. Gel permeation chromatography was used to measure the molecular weight of polymers 446 and 7,8-4-J11, respectively. The number averaged molecular weight (Mn) was 5935 Da for 446 and 6943 Da for 7,8-4-J11. Using polymer Mn and the molecular weight of individual monomers, the nitrogen (N) weight fraction was calculated to be 0.055 for 446 and 0.046 for 7,8-4-J11. The average phosphate (P) weight fraction for DNA was calculated to be 0.095. Taken together, 446 nanoparticles at 60 w/w had an N-P ratio of 34.5, and 7,8-4-J11 nanoparticles at 30 w/w had an N-P ratio of 14.5.